Protagonist Therapeutics, Inc.

7707 Gateway Boulevard
Suite 140
Newark
California
94560
United States

Tel: 650-587-5766
Fax: n./a

Website: http://www.protagonist-inc.com/

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.

YEAR FOUNDED:

2001

LEADERSHIP:

Founder: Mark Symythe

CEO: Dinesh Patel

CMO (Marketing): Richard Shames

CFO: Tom O’Neil

CSO (Scientific): David Liu

JOBS:

Please click here for Protagonist Therapeutics job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

185 articles with Protagonist Therapeutics, Inc.

Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress

6/4/2020

Protagonist Therapeutics, Inc. announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-thalassemia at the 25th European Hematology Association Annual Congress, which will take place in a virtual format June 11-14, 2020.
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences in June 2020

5/28/2020

Protagonist Therapeutics, Inc. announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming virtual healthcare investor conferences.
Protagonist Therapeutics, Inc. Announces Upsizing and Pricing of Underwritten Public Offering of 7,000,000 Shares of Common Stock

5/12/2020

Protagonist Therapeutics, Inc., a clinical stage biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share.
Protagonist Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Common Stock - May 11, 2020

5/11/2020

Protagonist Therapeutics, Inc., a clinical stage biopharmaceutical company, announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.
Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

5/7/2020

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the first quarter ended March 31, 2020, and provided an update on clinical development programs.
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

5/7/2020

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced initial data from the ongoing Phase 2 study of PTG-300 in patients with polycythemia vera.
Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update

5/4/2020

Protagonist Therapeutics, Inc. will announce first quarter financial results after the NASDAQ market closes on Thursday, May 7, 2020.
Protagonist Therapeutics Reports Granting of Inducement Award - April 15, 2020

4/16/2020

Protagonist Therapeutics, Inc. reported that on April 15, 2020, it issued an inducement award to Tracy Woody, the Company's recently hired Executive Vice President of Corporate Strategy, in accordance with the terms of Ms. Woody's employment offer letter.
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

3/10/2020

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its clinical development programs.
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results

3/2/2020

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) will announce fourth quarter and year end 2019 financial results after the NASDAQ market closes on Tuesday, March 10, 2020 .
Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York

2/19/2020

NEWARK, Calif. , Feb. 19, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annual Global Healthcare Conference in New York . Presentation details: Event: SVB Leerink 9th Annual Global Healthcare Confere
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO)

2/7/2020

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will present preclinical data on PN-943, the Company's oral, gut-restricted, alpha-4-beta-7 inhibitor candidate therapeutic, at the 15th Congress of the European Crohn's and Colitis Organization (ECCO), which will take place Feb. 12-15, 2020 , in Vienna
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration

1/7/2020

An oral, gut-restricted IL-23 receptor antagonist peptide is successfully nominated as a second-generation development candidate, advancing the collaboration and triggering a $5M milestone payment
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

1/6/2020

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been initiated
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia

12/3/2019

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced preliminary results from patients with transfusion-dependent (TD) beta-thalassemia in the ongoing TRANSCEND Phase 2 open-label study of PTG-300.
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences

11/13/2019

Protagonist Therapeutics, Inc. announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences in New York..
Protagonist Therapeutics Reports Third Quarter 2019 Financial Results

11/6/2019

Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease

11/6/2019

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first patient has been dosed in a Phase 2 study of PTG-200 (also referenced as JNJ-67864238) in patients with moderate to severe Crohn's disease
Protagonist Therapeutics Secures Debt Facility for up to $50 Million

10/31/2019

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced it has entered into a four-year debt facility with MidCap Financial (MidCap), the lead agent, and Silicon Valley Bank (SVB).
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera

10/30/2019

Protagonist Therapeutics, Inc. announced that the first patient has been dosed in a Phase 2 study of PTG-300 in patients with polycythemia vera, a myeloproliferative disorder characterized by overproduction of red blood cells..